Insights

DISCOVER

COMPANY

Survey

SURVEY

Consulting

COUNSULTING

Create New Account

Book discovery call

Central and Eastern Europe OTC Drugs Industry Outlook to 2017

Expanding Access to Distribution Channels to Lead Sales Growth

Region:Europe

Product Code:KR118

Download Sample Report

Published On

January 2014

Total pages

Download Sample Report

About the Report

The report titled “Central and Eastern Europe OTC Drugs Industry Outlook to 2017- Expanding Access to Distribution Channels to Lead Sales Growth” presents a comprehensive analysis of the industry covering aspects including market size by revenue and market segmentation by cold and cough medications, analgesics, digestives, skin treatment products, vitamin and mineral supplements and others and by geography including Russia, Poland, Ukraine, The Czech Republic, Romania, Hungary, Slovakia and Bulgaria. The report also entails a detailed description on the recent trends and developments in the market in the region and competitive scenario of major players in major geographies.

With burgeoning wealth and increasing awareness of the advantages of good healthcare and healthier lifestyles, emerging markets across the globe such as that of Central and Eastern Europe, Latin America and Asia-Pacific countries are turning out to be significant markets for pharmaceutical drugs. OTC drugs market in Central and Eastern Europe is one of the most rapidly emerging markets for pharmaceuticals in the world. Surging acceptance of such drugs by the people, increased availability and wide spread usage of non-prescription drugs to treat minor ailments has resulted in rapid growth of the market in the region over the last few years.

The market has recorded remarkable growth over the last six years by growing at an average annual rate of 8.1% from 2006-2012. The total market value in the region was recorded to be USD ~ million in 2006 which rose to USD ~ million in 2012. Digestives are considered as one of the prime segments of the industry accounting for a total of ~% share in the market revenue in 2012. The market for OTC digestives in the Central and Eastern European region has grown at a pace of 6.8% over the period 2006-2012. Vitamins and mineral supplements have also considerably aided market growth in the region in the recent years. The market sales value have increased predominantly over the years from USD ~ million in 2006 to USD ~ million in 2012 due to the well educated population inclined towards the benefits of healthy living and wellness protocols.

Russia is the largest market for OTC medications in the region with a share of ~% in 2012 as compared to ~% in 2006. The sale of OTC drugs in Russia occurs through only the pharmacy chains. Pharmacy chain 36.6 is the largest pharmacy chain in Russia. In the Russian market for OTC medications, cold and cough medications commanded the largest share of ~% share of the total OTC drugs sales in the country in 2012 which has risen from ~% in 2006. OTC skin products held the fourth largest share of ~% in the OTC drugs market in Russia in 2012.
Pharmstandard is the largest company with a market share of ~%. The revenue from the sales of OTC drugs by the company was recorded as USD ~ million in 2012 as compared to USD ~ million in 2011.

The OTC drugs market in Poland is the second largest market in Central and Eastern European region accounting for a share of ~% in the overall market in 2012 In 2012, the OTC drugs market in Poland was valued at USD ~ million as compared to USD ~ million in 2011. Poland’s non-prescription drugs market has been largely held by the drugs used for treating cold, cough and other respiratory disorders. The segment accounted for the largest share of around ~% in the OTC drugs market revenue in the country in 2011 mainly due to the widespread flu among the people in the country. Painkillers/ analgesics were the third largest segment of the industry in 2012 accounting for ~% share in the market. The market is predominantly held by USP Zdrowie with a market share of ~% in 2012 followed by Aflofarm, GSK Consumer healthcare and Bayer sharing nearly ~%, ~% and ~% respectively.

Ukraine, the Czech Republic and Romania held the next leading positions in the market with a share of ~%, ~% and ~% respectively in 2012. Cold and cough medications have traditionally led the market for OTC medications in the Czech Republic with a share of ~% in 2012 as compared to ~% in 2006.

Hungary has one of the most developed pharmaceutical industries in the Central and East European region. Some of the leading non-prescription medicines manufactures in the country include Sanofi Aventis, Novartis, Bayer Hungaria, Novartis, Teva Magyarorszag, EGIS among others together accounting for a market share of ~% in 2012.

Key Topics Covered in the Report:

The market size of Central and Eastern Europe OTC Drugs Market in terms of revenue, 2006-2012
Market Segmentation in the region by product categories and by geography, 2006-2012
Market Share of Leading Players in overall OTC Drugs Market in Russia, Poland, Ukraine, Hungary
Market Share of Leading Players in different segments of OTC drugs in Russia
Revenues of Top 10 Pharmaceutical Companies in Romania by Sales Value of OTC Cold and Flu Drugs, 2012
Trends and Developments in the Central and Eastern Europe OTC Drugs industry and by geographies
Government Regulations in the Pharmaceutical Sector in each Geography (excluding Slovakia)
Competitive Landscape of Major Players in OTC Drugs Market in Russia, Poland, Ukraine and the Czech Republic.
Future Outlook and Projections of OTC Drugs market in each Geography in the region, 2013-2017

Products

Cold and Cough, Vitamins and Minerals, Digestives, Analgesics, Skin Products and Others otc drugs, pharmacy chains, medications, non-prescription

Companies

Sanofi Aventis, Novartis, Bayer Hungaria, Teva Magyarorszag, EGIS, USP Zdrowie, Aflofarm, GSK Consumer healthcare, Pharmstandard

1. Central and Eastern Europe OTC Drugs Market Introduction
1.1. Central and Eastern Europe OTC Drugs Market Size by Revenue, 2006-2012

2. Central and Eastern Europe OTC Drugs Market Segmentation, 2006-2012
2.1. By Product Categories, 2006-2012
2.2. By Geography, 2006-2012

3. Trends and Developments in Central and Eastern Europe Market
Mergers and Acquisitions in OTC Market in Central and Eastern Europe
Liberalization of OTC Drugs Distribution in 2011 in CEE
Online Sales of Drugs Permitted in Slovakia
Rearrangement of the Wholesale Market of Pharmaceuticals in the Region
Online sales of Drugs allowed in Bulgaria

4. Central and Eastern Europe OTC Drugs Market Future Outlook and Projections, 2013-2017
4.1. Central and Eastern Europe OTC Drugs Market Future Projections, 2013-2017
4.1.1. By Geography, 2013-2017
4.1.2. Cause and Effect Relationship Between Industry Factors and Central and Eastern Europe OTC Drugs Market Prospects

5. Russia OTC Drugs Market Introduction
5.1. Russia OTC Drugs Market Size, 2006-2012
5.1.1. By Revenue, 2006-2012
5.1.2. By Volume, 2008-2012
5.2. Russia OTC Drugs Market Segmentation, 2006-2012
5.2.1. By Cold and Cough, Analgesics, Digestives, Skin Products, Vitamins and Minerals and Others, 2006-2012
5.2.2. By Cities, 2012
5.3. Trends and Developments in Russia OTC Drugs Market
Approval of Selling of OTC Drugs in retail stores by Ministry of Healthcare
Appointment of New Government: Spurring Developments in Health Sector in Russia
Increasing Focus on Bio-Additives and Functional Nutrition
5.4. Government Regulations in Russia OTC Drugs Industry
Ban on Over the Counter Sales of Medical Drugs
Major Regulatory Changes in Russian Pharmaceutical Market in 2012
5.5. Market Share of Major Players in Russia OTC Drugs Market, 1H2013
5.5.1. By Anti Cold and Flu Drugs, 2012
5.5.2. By Non- Narcotic Analgesics and Antipyretic Drugs, 2012
5.5.3. By Expectorants & Antitussives (Cough Medications), 2012
5.5.4. By Multivitamins with Minerals, 2012
5.5.5. By Systematic Agents for Fungal Infections, 2012
5.6. Competitive Landscape of Major Players in RussiaOTC Drugs Market
5.7. Russia OTC Drugs Market Future Outlook andProjections, 2013-2017
5.8. Macro Economic Factors of Russia OTC Drugs Market: Historical and Projected
5.8.1. Population, 2006-2017
5.8.2. Public and Private Health Expenditure, 2006-2017
5.8.3. Consumer Price Index on Medicines, 2010-2012

6. Poland OTC Drugs Market Introduction
6.1. Poland OTC Drugs Market Size, 2006-2012
6.2. Poland OTC Drugs Market Segmentation, 2006-2012
6.2.1. By Products, 2006-2012
6.2.2. By Pharmacy and Non-Pharmacy Distribution Channel, 2011
6.3. Trends and Developments in Poland OTC Drugs Market
Rising Advertisement Expenditure by Pharmaceutical Companies
Plans to Launch New Products by Dietary Supplements Manufacturers
6.4. Government Regulations in Poland Pharmaceutical Market
General Overview
Reimbursement Act, 2012
6.5. Market Share of Major Players in Poland OTC Drugs Market, 2012
6.6. Competitive Landscape of Major Players in Poland OTC Drugs Market
6.7. Poland OTC Drugs Market Future Outlook and Projections, 2013-2017
6.8. Macro Economic Factors of Poland OTC Drugs Market: Historical and Projected
6.8.1. Population, 2006-2017
6.8.2. Health Expenditure Per Capita, 2006-2017
6.8.3. Consumer Price Index on Health, 2006-2012
6.8.4. Number of Pharmacies in Poland, 2006-2017

7. Ukraine OTC Drugs Market Introduction
7.1. Ukraine OTC Drugs Market Size, 2006-2012
7.2. Ukraine OTC Drugs Market Segmentation, 2006-2012
7.2.1. By Products, 2006-2012
7.3. Trends and Developments in Ukraine OTC Drugs Market
First Reading in Parliament on Act on Ban of Advertisement of OTC Medications in 2011
Act on Ban of Advertisements of OTC Medications Passed in 2012
Rapidly Changing Lifestyles Spurring OTC Drugs Sales
7.4. Government Regulations in Ukraine OTC Drugs Market
Permitting Drug Retail Only through Pharmacies
Rules Pertaining to Promotional Activities of Drugs
Recent Developments in Legal Regulation of Medicine and Healthcare in Ukraine
7.5. Market Share of Major Players in Ukraine OTC Drugs Market, 2012
7.6. Competitive Landscape of Major Players in Ukraine OTC Drugs Market
7.7. Ukraine OTC Drugs Market Future Outlook and Projections, 2013-2017
7.8. Macro Economic Factors of Ukraine OTC Drugs Market: historical and Projected
7.8.1. Population, 2006-2017
7.8.2. Health Expenditure of Households, 2006-2017
7.8.3. Consumer Price Index on Health, 2006-2012

8. The Czech Republic OTC Drugs Market Introduction
8.1. The Czech Republic OTC Drugs Market Size, 2006-2012
8.2. The Czech Republic OTC Drugs Market Segmentation, 2006-2012
8.2.1. By Products, 2006-2012
8.3. Trends and Developments in the Czech Republic OTC Drugs Market
Enactment of Reforms to Encourage Patients to Take greater Responsibility for Medical Treatment
Policies Geared Towards Reducing Costs in Healthcare
Restricted Development in 2008 due to Imposition of Mandatory Fees on Doctor Visit’s
Surging Investments in the Pharmaceutical Sector
8.4. Government Regulations on the Czech Republic Pharmaceutical Industry
General Overview
Mandatory Registration on Drugs for Manufacturing and Marketing
General Provisions on Promotion of Medicinal Products in the Market
8.5. Competitive Landscape of Major Players in the Czech Republic OTC Drugs Market
8.6. The Czech Republic OTC Drugs Market Future Outlook and Projections, 2013-2017
8.7. Macro Economic Factors of the Czech Republic OTC Drugs Market
8.7.1. Population, 2006-2017
8.7.2. Health Expenditure of Households, 2006-2017
8.7.3. Number of Pharmacies in the Czech Republic, 2006-2012
8.7.4. GDP (FROM Production Side), 2006-2017

9. Romania OTC Drugs Market Introduction
9.1. Romania OTC Drugs Market Size by Revenue and Volume, 2006-2012
9.2. Romania OTC Drugs Market Segmentation, 2006-2012
9.2.1. By Products, 2006-2012
9.3. Implication of Claw Back System in RomaniaPharmaceutical Industry
9.4. Trends and Developments in Romania OTC Drugs Market
Introduction of Clawback System Resulting in Rise in OTC Drugs Sales
Trends in Production of Pharmaceutical Drugs
9.5. Government Regulations in Romania Pharmaceutical Industry
Regulatory Framework: A General Overview
Pricing and Reimbursement Methodology
Pharmacy Law
9.6. Revenues of Top 10 Pharmaceutical Companies in Romania by Sales Value of OTC Cold and Flu Drugs, 2012
9.7. Romania OTC Drugs Market Future Outlook and Projections, 2013-2017
9.8. Macro Economic Factors of Romania OTC Drugs Market: Historical and Projected
9.8.1. Population, 2006-2017
9.8.2. Health Expenditure of Households, 2006-2017
9.8.3. Number of Pharmacies and Pharmaceutical Points in Romania, 2006-2017

10. Snapshot of Countries in OTC Drugs Market in Central and Eastern Europe
10.1. Hungary
10.1.1. Hungary OTC Drugs Market Size and Segmentation, 2006-2012
10.1.2. Distribution Channels of OTC Drugs in Hungary, 2012
10.1.2.1. Major OTC Products Sold in Pharmacies in Hungary, 2012
10.1.3. Recent Trends and Developments in Hungary OTC Drugs Market
Pharmacies in Hungary Permitted to Sell OTC Drugs Online
Reduced Spending by Pharmaceutical Companies in Hungary on Medical Journals in 2011
10.1.4. Hungary Pharmaceutical Regulatory Environment
Peculiar Taxes
Regulatory Framework Related to Opening of Pharmacies in Hungary
Regulations on Prices
Research and Development Based Tax Allowances
10.1.5. Market Share of Leading Players in Hungary OTC Drugs Market, 2012
10.1.6. Recent Developments of Companies in Hungary OTC Drugs Market
Government to co-found a company with vaccine manufacturer Omninvest
Gedeon Richter establishes new joint venture in China
Egis considering more than one acquisition
10.1.7. Hungary OTC Drugs Market Future Outlook and Projections, 2013-2017
10.2. Slovakia
10.2.1. Slovakia OTC Drugs Market Size and Segmentation, 2006-2012
10.2.2. Recent Trends and Developments in Slovakia OTC Drugs Market
Online Sales of OTC Drugs Permitted in Slovakia
Pricing structure
10.2.3. Slovakia OTC Drugs Future Outlook and Projections, 2013-2017
10.3. Bulgaria
10.3.1. Current Position, 2012
10.3.2. Bulgaria OTC Drugs Market Size and Segmentation, 2006-2012
10.3.3. Recent Trends and Developments in Bulgaria OTC Drugs Market
Legal Approval of Online Sales of OTC Drugs in Bulgaria
Bulgaria Pharma Market: 2012 Trends
10.3.4. Government Regulations in Bulgaria Pharmaceutical Market
Pricing System
10.3.5. Competitive Scenario of Major Players in Bulgaria OTC drugs Market
10.3.6. Bulgaria OTC Drugs Market Future Outlook and Projections, 2013-2017

11. Appendix
11.1. Market Definitions
11.2. Abbreviations
11.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
11.4. Disclaimer

Why Buy From Us?

Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository

150+ Consulting project a year

100+ Analysts

8000+ Client Queries in 2022